PERIMETER MED IMAGING AI - PYNKF STOCK NEWS

Perimeter Medical Imaging AI will host an investor webcast on June 25, 2024, at 2:00 PM ET. The event will feature presentations from CEO Adrian Mendes, CIO Andrew Berkeley, and CFO Sara Brien, focusing on key business areas. Investors can engage in a live Q&A session. To participate, pre-register at the provided link. An archived version will be accessible on the company's website.

Perimeter Medical Imaging AI reported its Q1 2024 financial results, highlighting significant progress in clinical development and commercial expansion.

The company exceeded patient enrollment expectations in its pivotal clinical trial for the B-Series OCT with ImgAssist AI, leading to a decision to expedite full enrollment by early Q4 2024. Three new placements of the S-Series OCT system were completed, boosting market presence.

Financially, operating expenses rose to $4.7 million, but net loss decreased to $2.1 million compared to Q1 2023. Cash and equivalents stood at $10.6 million as of March 31, 2024.

A conference call is scheduled for 5 pm ET to discuss the results and provide further updates.

Perimeter Medical Imaging AI, Inc. (PYNKF) will release its first quarter 2024 financial results on May 14, 2024, followed by a conference call hosted by CEO Adrian Mendes. The call will discuss the results and provide a corporate update. Investors can join the call online or via phone.

Perimeter Medical Imaging AI announces a webinar featuring AI expert Anantha Kancherla discussing trends in the use of machine learning and artificial intelligence in healthcare applications. The webinar showcases Perimeter's leadership in applying AI tools to their product pipeline and leveraging a large proprietary image data set for training models.

Perimeter Medical Imaging AI, Inc. (PYNKF) to showcase S-Series OCT device at ASBrS, grants stock options, and engages Velocity Trade for market liquidity services.

Perimeter Medical Imaging AI, Inc. reported financial results for Q4 and year-end 2023, highlighting progress in infrastructure, clinical education, AI development, and clinical trials. The company's CEO outlined plans for growth, product innovation, and market expansion, emphasizing successful implementation of enhanced AI in clinical trials. Financially, operating expenses increased slightly, resulting in a higher net loss compared to the previous year. Cash used in operating activities was significant, with cash and equivalents slightly lower at the end of 2023.

Perimeter Medical Imaging AI, Inc. announces upcoming events and grant funding opportunities to support AI technology development. The company will showcase its Perimeter S-Series OCT technology at an international conference.

Perimeter Medical Imaging AI, Inc. announced positive results from a study on Wide Field Optical Coherence Tomography (WF-OCT) and AI technology in breast cancer surgery. The AI model showed high sensitivity and specificity, potentially reducing reoperation rates. Perimeter's CEO highlighted the AI's potential in improving surgical outcomes and expanding market reach. An ongoing clinical trial led by Dr. Alastair Thompson aims to evaluate Perimeter's technology further.

Perimeter Medical Imaging AI, Inc. (PYNKF) releases study results on reoperation rates after breast-conserving surgery, highlighting high costs and risks. The study emphasizes the need for improved margin assessment methods to reduce reoperation rates and complications.